Document:

fzmd-ex1025_75.htm

EXHIBIT 10.25

SALES AGENCY AGREEMENT

THIS SALES AGENCY AGREEMENT (this “Agreement”) is made this 1st day of August 2018, by and between StelKast, Inc., a Pennsylvania corporation (“StelKast”), and CPM Medical Consultants, LLC, an independent sales representative with its principal office located at 1565 N. Central Expy., Suite 200, Richardson, TX 75080, (“Agent”).

NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby

acknowledged, the parties hereto agree as follows with the intent to be legally bound:

ARTICLE I.
DEFINITIONS 

When used throughout this Agreement, the following words shall have the meaning herein defined.

Section 1.1.Laws.  The term “Laws” shall mean every law, rule, regulation, policy, code, ordinance, interpretive rule and instruction, restriction, order, writ, injunction or decree of any court, administrative agency or governmental or regulatory body.

Section 1.2.Product.  The term “Product” or “Products” shall mean StelKast hip and knee implants identified on Exhibit A which are not separately reimbursed by any federal health care program. Exhibit A may be unilaterally updated from time to time by StelKast.

Section 1.3.Specified Area. The term “Specified Area” shall mean the accounts set forth on Exhibit B as long as Agent maintains sales at those accounts. Additional accounts may be added as mutually agreed on in writing by StelKast and Agent. For the avoidance of doubt, the designation of the Specified Area is not intended nor shall it be construed to grant Agent exclusive rights to the Specified Area.

Section 1.4.Medical Device Excise Tax.  The term “Medical Device Excise Tax” shall mean the taxes imposed upon the sale of medical devices as defined under Internal Revenue Code Section 4191, which was enacted by the Health Care and Education Reconciliation Act of 2010.

Section 1.5.Net Sales Price. The term “Net Sales Price” shall mean the total price invoiced and paid by the hospital account less the amount of any rebate, fee, applicable Medical Device Excise Tax, or other amount due from StelKast in respect of such sale (including, without limitation, the amount of any rebate payable in connection therewith or any fee or other expense payable to the hospital account or a purchasing organization acting on behalf of such hospital account in connection therewith).

1

 

 

 

ARTICLE II.
NATURE OF ENGAGEMENT

Section 2.1.Appointment.  StelKast hereby appoints Agent as an independent sales representative in the Specified Area to solicit orders in accordance with the terms of this Agreement. Orders may be solicited only from licensed health care facilities or group purchasing organizations for such facilities.

Section 2.2.Quotations.  All quotations made by Agent shall be on StelKast’s terms and conditions. All prices, terms and conditions shall be subject to revision by StelKast until the time of acceptance of the order. All quotations of Agent shall contain a statement to that effect.

Section 2.3.Customer Development.  Agent shall:  (i) use its best efforts to solicit orders for Products; and (ii) provide coverage of accounts on a regular basis, consistent with good business practices and in accordance with all applicable Laws.

Section 2.4.Agent’s Additional Duties.

(a)Agent’s duties shall also include, but will not be limited to, the following: (i) to verify customer complaints within the Specified Area and to offer competent solutions; (ii) to assist StelKast in the collection of accounts within the Specified Area, including invoicing customers; (iii) to advise StelKast of any request of a potential customer within the Specified Area for information relating to any of StelKast’s products or services, giving full details concerning the requirements of the potential customer; (iv) to provide administrative assistance to StelKast when required; and (v) to inform StelKast of any malfunction or failure of any Product of which Agent becomes aware.

(b)Agent will be solely responsible for all travel and other expenses incurred by Agent in carrying out its obligations under this Agreement.

Section 2.5.Representations. Agent shall make no representations, claims, or warranties with respect to the Products, either orally or in writing, unless such representations, claims or warranties have been previously approved by StelKast in writing. StelKast will not be bound in any manner whatsoever should Agent make such representations, claims, or warranties in violation of this Agreement.

Section 2.6.Authority. Agent shall not have the right or power to enter into any contract on StelKast’s behalf, nor to bind StelKast in any respect.

Section 2.7.Independent Contractor. Agent is and shall remain at all times an independent contractor. No provision of this Agreement is intended to create or shall create any other relationship, such as employment, joint venture, partnership, or agency, between StelKast and Agent. Agent shall pay all the expenses incurred in connection with this Agreement and shall be solely responsible for the acts of its employees, subagents, representatives, agents, consultants, and contractors. Agent acknowledges that it is responsible for the payment of all taxes with regard to the receipt of the compensation payable under Article IV hereof. Agent shall 

- 2 -

 

 

have sole responsibility for withholding any sums for income tax, unemployment insurance, social security or any other withholding required by applicable law or governmental requirement for its employees, subagents, representatives, agents, consultants, and contractors, as required by law. Agent shall indemnify and hold StelKast and its shareholders, directors, and officers and their respective affiliates harmless from and against any employment related claim, whether for wages, benefits, unemployment, workers’ compensation or tax liability. No person hired by Agent to provide any services in connection with this Agreement shall for any purpose at any time be deemed to be an employee or contractor of StelKast, and StelKast shall have no obligation to any such individual for wages, benefits, workers’ compensation, disability, unemployment, or any withholding or other taxes.

ARTICLE III.
STELKAST’S RIGHTS

Section 3.1.Acceptance. All orders taken by Agent shall be subject to StelKast’s written acceptance, and all quotations of Agent shall contain a statement to that effect. StelKast shall have the absolute right to accept or reject any order or any part thereof.

Section 3.2.Conditions of Sale. StelKast shall, in its sole discretion, determine the conditions of sale and whether or not credit terms shall be extended, and all quotations of Agent shall contain a statement to that effect.

Section 3.3.Modifications of Scope. At any time, StelKast may, in its absolute discretion, withdraw any Product or any part of the Specified Area from the scope of this Agreement by giving written notice to Agent.

ARTICLE IV.
COMPENSATION 

Section 4.1.Compensation and Commissions. Agent will be compensated and paid a commission on the sale of Products in accordance with Exhibit C.

ARTICLE V.
METHOD OF PERFORMANCE

Section 5.1.Dealings with Governments. Throughout the term of this Agreement, Agent shall, and shall ensure that its employees, subagents, representatives, agents, consultants, contractors and affiliates will, neither make nor promise to make any gift or payment of money or anything of value either directly or indirectly to any officer or employee of any government or any department or agency thereof, or to any political party or candidate for political office for the purpose of inducing such official, employee, party or candidate to misuse his or her position or to influence any act or decision of any government in order to obtain, retain or direct business to StelKast or any subsidiary or affiliate thereof.

Section 5.2.Compliance with Legal and StelKast Requirements.

(a)Throughout the term of this Agreement, Agent shall, and shall ensure that its employees, subagents, representatives, agents, consultants, contractors and 

- 3 -

 

 

affiliates will, comply with (i) all applicable Laws, including, without limitation compliance with the federal Medicare and Medicaid statutes, the federal Anti-Kickback Statute, the federal False Claims Act, the federal Self-Referral Statute, and the regulations promulgated pursuant to such statutes and related state or local statutes or regulations; and (ii) all policies, procedures and programs of StelKast as may be adopted and/or amended from time to time, including, but not limited to, compliance programs that are communicated to Agent.

(b)Throughout the term of this Agreement, Agent shall, and shall ensure that its employees, subagents, representatives, agents, consultants, contractors and affiliates will, (i) not offer, pay, solicit, or receive any gift or payment of money or anything of value either directly or indirectly to or from any individual or entity in order to improperly induce referrals of items or services reimbursable under any Federal health care program, (ii) not recommend Products for non-approved uses, and (iii) not relay inaccurate or misleading information regarding Medicare, Medicaid or other third party payor coverage, coding or billing of Products or procedures using Products.

(c)Throughout the term of this Agreement, Agent hereby represents and warrants to StelKast that no physician or a physician’s immediate family member will provide services under this Agreement.

(d)Throughout the term of this Agreement, Agent shall ensure that all of its employees, representatives, agents and subcontractors ("Representatives") are properly trained in basic sterile technique in the operating room, and Agent hereby represents and warrants to StelKast that Agent and its Representatives are in compliance with the foregoing as of the date hereof. In addition, Agent acknowledges and agrees that it and its Representatives are required to undergo training regarding, and be proficient in and knowledgeable about, all StelKast implant system surgical techniques, product specifications, warnings, precautions, and instructions provided by or on behalf of StelKast (collectively, "StelKast Product Training"). StelKast Product Training will be provided by StelKast to Agent and/or its Representatives upon the reasonable request of Agent either (i) at StelKast's offices or (ii) remotely via a self-administered training program, in either case as mutually agreed by StelKast and Agent. Agent shall, and shall cause its Representatives to, execute and deliver to StelKast, upon request, a written certification in a form provided by StelKast certifying as to the completion by each of them of the StelKast Product Training. In addition to StelKast Product Training, Agent shall, and shall cause its Representatives to, accurately and timely complete all vendor credentialing requirements of any hospital system or other account from which Agent solicits orders pursuant to this Agreement, and shall, and shall cause its Representatives to, execute and deliver to StelKast, upon request, a written certification in a form provided by StelKast certifying as to the satisfaction of such vendor credentialing requirement.

Section 5.3.Inventory Policies

(a)From time to time during the Term of this Agreement, StelKast may provide Products, samples and/or instruments (collectively, "Inventory") to Agent to be 

- 4 -

 

 

held by Agent, as bailee, pursuant to the terms of this Agreement. From and after delivery of Inventory to Agent, Agent is responsible for all loss of or damage to the Inventory. Without limiting the generality of the foregoing, Agent shall provide a safe and secure environment for the storage of the Inventory.

(b)Agent shall, at Agent's sole expense, conduct a semiannual count of the Inventory (or more frequently if requested by StelKast) and shall deliver the results of the same to StelKast. In addition, Agent shall grant StelKast or its Representatives access to the Inventory at any time upon reasonable prior notice. If, at any time, it is discovered that any Inventory bailed to Agent is damaged or missing, Agent shall immediately pay to StelKast the list price for the damaged or missing Inventory then in effect. Failure to do so shall constitute grounds for the immediate termination by StelKast of this Agreement pursuant to Section 7.2.

(c)Promptly upon StelKast's request for any reason, Agent shall return the Inventory to StelKast. Agent shall be responsible for the cost of delivering such Inventory to StelKast, and Agent shall retain the risk of loss or damage to the Inventory until the same has been delivered to StelKast. Agent acknowledges that Products are regulated by the Food and Drug Administration and that there may be times when it is imperative that materials be pulled from the shelves and returned to StelKast. Failure to comply with any request to return materials shall constitute grounds for the immediate termination by StelKast of this Agreement pursuant to Section 7.2.

(d)In addition to the rights set forth on Exhibit C, StelKast reserves the right to offset against commissions or other money payable to Agent any amounts that Agent owes to StelKast under the provisions of this Section5.3.

Section 5.4.Other StelKast Policies

Agent shall comply with such other written policies of StelKast as are in effect from time to time, including, without limitation, the Loaner Instrument and Implant Policy and the Shipping Policy set forth on Exhibit D.

ARTICLE VI.
INTELLECTUAL PROPERTY AND PROPRIETARY INFORMATION

Section 6.1.Use of Intellectual Property. Agent may not use StelKast’s trademarks, service marks, trade names, copyrights, or patents (“Intellectual Property”) in any manner, except as authorized by StelKast. Any and all use of StelKast’s Intellectual Property by Agent shall inure to and be for the benefit of StelKast. Agent shall discontinue any and all use of StelKast’s Intellectual Property upon termination of this Agreement for any reason.

5

Section 6.2.Proprietary Information. All data, literature and information in any form, not in the public domain, that is transferred by either party to the other shall be considered proprietary information (“Proprietary Information”) during and following the term of this Agreement, whether or not it is expressly marked proprietary, and shall not be revealed or 

- 5 -

 

 

transferred by the recipient to any other person, third party, company or otherwise without the prior written authorization of the disclosing party, nor shall either party be considered to have relinquished any of such party’s rights in the Proprietary Information at any time by a transfer within the scope of this Agreement.

Upon request of either party or upon expiration or termination of this Agreement, whichever occurs first, each party will submit to the requesting party all whole and partial copies of all Proprietary Information disclosed, obtained, generated or otherwise supplied to such party by the other party under and within the scope of this Agreement. Any information, including, but not limited to, reports, data or other such similar items, supplied by one party to the other party within the scope of this Agreement will be for the exclusive use of the other to carry out the purposes of this Agreement and for no other purpose. Each party agrees not to use any of the Proprietary Information supplied by the other party to manufacture products, machines, or parts or to have such products, machines or parts manufactured by others for any other purpose whatsoever other than acting as Agent hereunder or a manufacturer, developer or seller of the Products.

ARTICLE VII.
DURATION, TERMINATION, AND RENEWAL

Section 7.1.Effective Date.  This Agreement shall become effective when signed by both parties, and shall continue in effect until terminated in accordance with this Agreement.

Section 7.2.Termination with Notice.  StelKast or Agent may terminate this Agreement at any time without cause and without payment of any kind upon 30 days written notice to the other party; provided, however, that StelKast may terminate this Agreement pursuant to Section 5.3 immediately upon the giving of written notice thereof.

Section 7.3.Termination without Notice.  This Agreement shall terminate immediately, without notice or payment of any kind:

(a)upon the institution by or against Agent of proceedings in bankruptcy or any other procedure for the settlement of debts;

(b)upon Agent’s making an assignment for the benefit of creditors;

(c)upon Agent’s dissolution;

(d)upon Agent becoming the subject of an investigation by the Centers for Medicare or Medicaid Services, the Office of Inspector General, or other federal or state regulatory agency;

(e)Agent’s suspension or exclusion from participation in the Medicare and/or Medicaid programs or debarment by any federal agency;

(f)upon the felony conviction of Agent or its Representatives;

- 6 -

 

 

(g)if Agent engages in:  (i) sales and other activities in violation of applicable Laws, (ii) misrepresentation, misbranding or adulteration of any of StelKast’s products, (iii) violation of any of StelKast’s policies communicated to Agent, (iv) any action or statement which is or could be detrimental to the reputation or goodwill of StelKast, (v) requesting or requiring that customers remit payment for Products directly to Agent, or (vi) selling Products to parties who use, resell or distribute such Products outside of the United States; or

(h)in the event of a breach of Article VI of this Agreement.

ARTICLE VIII.
MISCELLANEOUS PROVISIONS 

Section 8.1.Limitation of Liability.  StelKast will under no circumstance be liable to Agent or any third parties for any special, indirect, or consequential damages, including, but not limited to, loss of profits or loss of business opportunities even if StelKast is advised of the possibilities of such damages.

Section 8.2.Assignment.  This Agreement may not be assigned by Agent in whole or in part, without the prior written consent of StelKast.

Section 8.3.Pricing and Intellectual Property Issues.  The prices paid by each user of Products are determined by contract between StelKast and the end user. Agent has no authority to change this pricing or to disclose the pricing offered to other users. In addition, Agent has no authority to use the StelKast name beyond that expressly granted to Agent in this Agreement. This means, among other things, that StelKast branded instruments may only be used in connection with procedures involving StelKast branded implants. Failure to adhere to these contractual requirements could have material and adverse effects on StelKast, its Intellectual Property, Proprietary Information, and its relationships with its customers and will thus be treated by StelKast as a material breach of this Agreement.

Section 8.4.Indemnification. 

(a)Agent shall indemnify, defend, save, and hold harmless StelKast and its officers, directors, shareholder, employees, agents, successors and permitted assigns (collectively, the “Indemnitees”), from and against any and all claims, losses, liabilities, costs, expenses, obligations, damages and attorneys’ fees (whether threatened or actually brought against or incurred by any Indemnitee) (the "Losses"), including, without limitation, any Losses that arise out of, result from, or relate to (i) any false representation or breach of warranty made by Agent under this Agreement, (ii) any non-compliance with or breach of any covenant, commitment or obligation by Agent under this Agreement, and/or (iii) any acts or omissions by Agent, its employees, subagents, representatives, agents, consultants, or contractors in the distribution, solicitation, or support of Products. Each of the indemnification obligations set forth in this Section shall survive the termination or expiration of this Agreement for any reason.

(b)StelKast shall indemnify, defend, save and hold harmless Agent from and against any and all losses, liabilities, costs, expenses, obligations, damages and 

- 7 -

 

 

attorneys’ fees actually incurred by Agent in connection with a third party claim against Agent seeking damages due to (i) the defective design and/or manufacture of Products or (ii) the infringement by any Product of a duly issued United States Patent.

Section 8.5.Waiver.  The failure of either party to enforce at any time any of the provisions, rights, or options of this Agreement shall in no way be considered to be a waiver of such provision, right, or option or in any way to affect the validity of this Agreement nor shall any waiver of any simple breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.

Section 8.6.Governing Law.  This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of Pennsylvania.

[signatures on following page]

 

 

- 8 -

 

EXHIBIT 10.25

IN WITNESS WHEREOF, the parties hereto have set their hands.

STELKAST, INC.

By:  
Name:  Jason Samler
Title: Contract Manager
Date:  9/18/2018 12:01:21 PM PDT

[Agent]

By:  
Name:  Houston Jimenez
Title:  Director of Sales
Date:  9/18/2018 11:59:49 AM PDT

 

 

 

EXHIBIT A - PRODUCTS

PRIMARY TOTAL HIP SYSTEM LISTING

		
	
PRODUCT DESCRIPTION
	
CATALOG 
NUMBER

	
Protract Plasma Standard Stem 

Protract Plasma Lateralized Stem
	
SC2659

SC2660

	
Protract HA Standard Stem 

Protract HA Lateralized Stem
	
SC2661

SC2662

	
Progeny Standard Stem 

Progeny Lateralized Stem
	
SC2069

SC2076

	
Progeny Distal Centralizer
	
SC2077

	
Provident Standard Stem 

Provident Lateralized Stem
	
SC2647

SC2658

	
ProClass Standard Stem 

ProClass Lateralized Stem
	
SC2656

SC2657

	
DTW Stem
	
SC1439

	
36mm CoCr Femoral Head

32mm CoCr Femoral Head

28mm CoCr Femoral Head

22mm CoCr Femoral Head
	
SC3261 / SC3346 
SC2271 / SC2272 
SC1151 / SC1152 
SC1444

	
36mm Ceramic Femoral Head (BIOLOX delta)

32mm Ceramic Femoral Head (BIOLOX delta)

28mm Ceramic Femoral Head (BIOLOX delta)
	
SC3295

SC3348

SC3347

	
Provident Plasma Spray Shell
	
SC1217 / SC3546

	
Cross-Over Acetabular Shell
	
SC3458

	
Hooded 36mm EXp Acet. Shell Liner

Non-Hooded 36mm EXp Acet. Shell Liner

Hooded 36mm Cross-Over EXp Acet. Shell Liner

Non-Hooded 36mm Cross-Over EXp Acet. Shell Liner

Hooded 32mm EXp Acet. Shell Liner

Non-Hooded 32mm EXp Acet. Shell Liner

Hooded 28mm EXp Acet. Shell Liner

Non-Hooded 28mm EXp Acet. Shell Liner
	
SC3349

SC3260

SC3474

SC3459

SC3345

SC3344

SC3343

SC3342

	
Hooded 32mm ProAr Acet. Shell Liner 

Non-Hooded 32mm ProAr Acet. Shell Liner 

Hooded 28mm ProAr Acet. Shell Liner 

Non-Hooded 28mm ProAr Acet. Shell Liner
	
SC2398

SC2397

SC2543

SC2542

	
Hooded 28mm Acet. Shell Liner 

Non-Hooded 28mm Acet. Shell Liner 

Hooded 22mm Acet. Shell Liner
	
SC1175

SC1163

SC1411

	
6.5mm Cancellous Bone Screw
	
SC1156 / SC2677

	
Unipolar Head
	
SC1401

	
Argomedical Bipolar Head
	
SC1866

 

- 10 -

 

 

EXHIBIT A (cont.)

PRIMARY TOTAL KNEE SYSTEM LISTING

		
	
PRODUCT DESCRIPTION
	
CATALOG 
NUMBER

	
Proven Gen-Flex PS Cemented Femur — Left 

Proven Gen-Flex PS Cemented Femur — Right
	
SC2953

SC2954

	
Proven Knee — PS Tibial Insert
	
SC1586

	
Proven Knee — PS Tibial Insert, Vitamin E X-Linked (EXp)
	
SC3425

	
Proven Knee — CR Cemented Femur — Left 

Proven Knee — CR Cemented Femur — Right
	
SC2038

SC2039

	
Proven Knee — Porous CR Femur — Left 

Proven Knee — Porous CR Femur — Right
	
SC2113

SC2114

	
Proven Knee — CR Tibial Insert — HF (Hi Flexion)
	
SC2829

	
Proven Knee — CR Tibial Insert — HF, Vitamin E X-Linked (EXp)
	
SC3453

	
GENFlex2 Knee — PS Cemented Femur — Left 

GENFlex2 Knee — PS Cemented Femur — Right
	
SC3749

SC3750

	
GENFlex2 Knee — PS Tibial Insert
	
SC3753

	
GENFlex2 Knee — PS Tibial Insert, Vitamin E X-Linked (E)(p)
	
SC3802

	
GENFlex2 Knee — CR Cemented Femur — Left 

GENFlex2 Knee — CR Cemented Femur — Right
	
SC3751

SC3752

	
GENFlex2 Knee — Porous CR Femur — Left 

GENFlex2 Knee — Porous CR Femur — Right
	
SC3857

SC3858

	
GENFlex2 Knee — CR Tibial Insert — HF (Hi Flexion)
	
SC3754

	
GENFlex2 Knee — CR Tibial Insert — HF, Vitamin E X-Linked (EXp)
	
SC3803

	
GENFlex2 Knee — CR Tibial Insert — UC (Ultra-Congruent)
	
SC3915

	
GENFlex2 Knee — CR Tibial Insert — UC, Vitamin E X-Linked (EXp)
	
SC3916

	
Proven Knee — Cemented Tibial Tray
	
SC1584

	
Proven Knee — 3-Peg Poly Patella
	
SC1591

	
Proven Knee — 1-Peg Poly Patella
	
SC1592

	
Proven Knee — 3-Peg Poly Patella, Vitamin E X-Linked (EXp)
	
SC3454

	
Proven Knee — 1-Peg Poly Patella, Vitamin E X-Linked (EXp)
	
SC3426

	
Unicondylar Femur — LM/RL 

Unicondylar Femur — RM/LL
	
SC2461

SC2462

	
Unicondylar Tibial — Inlay
	
SC2380 / SC3405

 

- 11 -

 

 

EXHIBIT A (cont.)

REVISION KNEE SYSTEM LISTING

		
	
PRODUCT DESCRIPTION
	
CATALOG 
NUMBER

	
Proven — Constrained/Revision Femur, Left 

Proven — Constrained/Revision Femur, Right
	
SC2957

SC2958

	
Proven — Constrained/Revision Valgus Bushing
	
SC2193

	
Femoral Augment — Distal 

Femoral Augment — Posterior
	
SC2316

SC2317

	
Proven — Femoral & Tibial Stem 

Femoral & Tibial Stem - Cemented
	
SC2196

SC3029

	
Proven — Revision Tibial Tray
	
SC2241

	
Proven — Revision Tibial Bushing
	
SC2240

	
Proven — % Tibial Block (w/screws)
	
SC2287

	
Proven — Constrained/Revision Insert
	
SC2265

	
Proven — Modular Tibial Tray
	
SC2291

	
Proven — % Tibial Block (w/o screws)
	
SC2295

 

DISPOSABLE COMPONENT PRICE LIST

		
	
PRODUCT DESCRIPTION
	
CATALOG NUMBER

	
1/8" DRILL BIT 3" LONG
	
SC1661

	
1/8" DRILL BIT 4" LONG
	
SC1662

	
1/8" QUICK CONNECT DRILL BIT
	
SC1953

	
FIXATION PIN-1/8" X 3",CUP PT.,HEADLESS
	
SC1841-1

	
FIXATION PIN-1/8" X 3",CUP PT.,HEADED
	
SC1841-2

	
FIXATION PIN-1/8" X 1.75",CUP PT.,HEADED
	
SC1841-3

	
FIXATION PIN-1/8" X 1",CUP PT.,HEADED
	
SC1841-4

	
FIXATION PIN-1/8" X 2",CUP PT.,HEADED
	
SC1841-5

	
FIXATION PIN-1/8" X 3",NAIL PT.,HEADLESS
	
SC2110-1

	
FIXATION PIN-1/8"X 2.5"
	
SC2110-2

	
FIXATION PIN-1/8" X 3",NAIL PT.,HEADED
	
SC2115-1

	
FIXATION PIN-1/8" X 2.5",NAIL PT.,HEADED
	
SC2115-2

	
FIXATION PIN-1/8" X 2",NAIL PT.,HEADED
	
SC2115-3

	
FIXATION PIN-1/8" X 1.75",NAIL PT,HEADED
	
SC2115-4

	
FIXATION PIN-1/8" X 1",NAIL PT.,HEADED
	
SC2115-5

	
FIXATION PIN-1/8" X 4", NAIL PT, HEADED
	
SC2115-6

	
THREADED BONE PIN w/COLLAR, 55MM
	
SC3520-55

	
THREADED BONE PIN, 65MM
	
SC3520-65

	
THREADED BONE PIN, 85MM
	
SC3520-85

	
DRILL BIT W/COLLAR, INNOMED PIN DRIVER
	
SC3693-01

	
DRILL BIT W/O COLLAR, INNOMED PIN DRIVER
	
SC3693-02

 

- 12 -

 

 

EXHIBIT B

SPECIFIED AREA

		
	
Crescent Medical Center — Lancaster, TX

Hunt Regional Medical Center — Greenville, TX
	
Jack Thomas, M.D.

Jack Thomas, M.D.

	
 
	
 

	
Dallas Medical Center — Dallas, TX
	
Terry D. Madsen, M.D. Jack Thomas, M.D.

	
 
	
 

	
Methodist Charlton Medical Center — Dallas, TX
	
Clinton S. Bell, M.D. Jesus Rey II, M.D. 

Joseph M. Tejan, M.D. John Tenny, M.D.

 

	
 
	
 

	
North Texas Surgery Center — Dallas, TX
	
Clinton S. Bell, M.D. Jesus Rey II, M.D.

	
 
	
 

	
Pine Creek Medical Center — Dallas, TX
	
Clinton S. Bell, M.D. Jesus Rey II, M.D. 
John Tenny, M.D.

	
 
	
 

	
Baylor Medical Center of Plano — Plano, TX

Methodist McKinney Medical Center — McKinney, TX

McKinney Medical Center — McKinney, TX
	
Charles E. Toulsen, M.D.

Charles E. Toulsen, M.D. Charles E. Toulsen, M.D.

	
 
	
 

	
Del Sol Medical Center — El Paso, TX

The Hospitals of Providence — East Campus — El Paso, TX

El Paso Specialty Hospital — El Paso, TX

Mountain West Surgery Center — El Paso, TX

The Hospitals of Providence Memorial — El Paso, TX
	
Keith R. Johnson, M.D. Keith R. Johnson, M.D. Keith R. Johnson, M.D. Keith R. Johnson, M.D. 

	
 
	
 

	
Southwest General Hospital - San Antonio, TX
	
Elliot Clemence, M.D.

 

- 13 -

 

 

EXHIBIT C

TERMS OF COMPENSATION AND COMMISSION RATES

1.TERMS OF COMPENSATION 

Agent will be compensated in accordance with Section 2 of this Exhibit C for all orders for Products in the Specified Area that were (i) obtained by Agent and (ii) accepted by StelKast in accordance with the terms of this Agreement. Unless otherwise required earlier pursuant to an unwaivable provision of applicable law, commission checks shall be printed and mailed on the first business day of the month following the end of the month after the month in which the invoice(s) applying to a particular sale were issued. If an invoice in respect of which a commission has been paid to Agent hereunder is not paid within ninety (90) days of its issuance, StelKast shall have the right to offset against future commissions payable to Agent up to 50% of such future commissions until the amount of the commission previously paid in respect of such unpaid invoice is recouped by StelKast. If the average days outstanding for receivables in the Specified Area exceed seventy-five (75) days, StelKast shall thereafter have the right to change the payment terms set forth in Section 1 of this Exhibit C.

2.COMMISSION RATES 

Primary Total Hip & Knee Sales:

Agent shall be paid a commission on the Net Sales Price of components of the Products ("Product Components") minus the Agent Cost for Product Components as defined below:

Agent Cost for StelKast Product Components:

					
	
Any Stem
	
1,500
	
 
	
Cemented Femur
	
900

	
Metal Head
	
250
	
 
	
Primary Tray
	
900

	
Any Shell
	
700
	
 
	
Standard Insert
	
300

	
Any Liner
	
350
	
 
	
Patella
	
300

	
Primary Hip
	
2,800
	
 
	
Primary Knee
	
2,400

	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
Uni Femur
	
1200

	
 
	
 
	
 
	
Uni Insert
	
400

	
 
	
 
	
 
	
Unicondylar
	
1,600

	
Options:
	
 
	
 
	
 
	
 

	
Ceramic Head
	
475
	
 
	
Modular Tray
	
1,250

	
BiPolar Head
	
435
	
 
	
Tib/Fem Stem
	
750

	
 
	
 
	
 
	
EXp Insert
	
450

 

		
	
Revision Knee Sales:
	
20% commission on Net Sales Price to the Hospital less the Medical Device Excise Tax.

	
 
	
Maximum Revision discount of 30% off list.

- 14 -

 

 

 

Commission rates above are based on a minimum volume of 12 total joints per month and a utilization of consigned assets of 3 turns per set per month. The volume and utilization will be evaluated six (6) months after the start of business and quarterly thereafter. Commission rates may be adjusted based on asset utilization and written agreement between Agent and StelKast.

- 15 -

 

 

EXHIBIT D

LOANER INSTRUMENT AND IMPLANT POLICY

	
 
	
1.
	
All instrument/implant loaner requests must be made through the Business Development Manager and/or Customer Service with a minimum of twenty-four (24) hours' notice prior to shipment.

2.Agent is responsible for inbound freight cost.

3.StelKast will supply return labels with each loaner shipment.

	
 
	
4.
	
Loaner systems need to be return shipped to StelKast within two (2) business days following surgery. All instruments should be in the original configuration as received.

	
 
	
5.
	
Agent will incur an additional fee of $25 per day, per instrument tray not return shipped within two (2) business days following surgery.

	
 
	
6.
	
Agent will incur an additional fee of $50 per day, for missing implant inventory not return shipped within two (2) business days following surgery.

	
 
	
7.
	
If the items are needed for any additional time, this request must be made through the Business Development Manager and/or Customer Service.

SHIPPING POLICY

	
 
	
1.
	
New implant bank and instrument set requests require a forty-eight (48) hour notice to Customer Service prior to shipping.

2.New implant banks and instrument sets will ship via two (2) day shipping.

	
 
	
3.
	
Agent will be responsible for any incremental fees associated with expedited delivery for new implant banks and instrument sets.

4.Agent will be responsible for the shipping cost of inventory replenishments.

- 16 -fzmd-ex1026_98.htm

EXHIBIT 10.26

DISTRIBUTORSHIP AGREEMENT 

	
This Distributorship Agreement ("Agreement"), effective the 1st day of October 2015 (the "Effective Date"), is between Vivex Biomedical, I e., a Delaware corporation ("Company") and CPM Medical Consultants, LLC a  
	
LimitedLiabilityCompany, specifically including their affiliates and subsidiaries/(“Distributor")(individually "Party" and collectively "Parties").

This Agreement will not bind Company until countersigned by the Company's authorized representative, regardless of partial performance, and no performance by Company will constitute an agreement or ratification of this Agreement. This Agreement will be automatically rescinded without further acts of Company, and any offers will be revoked, if Distributor does not sign and return the Agreement to Company within 15 business days of the Effective Date. AS A MATERIAL CONDITION PRECEDENT TO ENTERING INTO THIS AGREEMENT, DISTRIBUTOR REPRESENTS AND WARRANTS THAT IT IS NOT AND SHALL NOT BECOME A PHYSICIAN-OWNED DISTRIBUTORSHIP ("POD"). NO DISTRIBUTOR AFFILIATES/SUBSIDIARIES THAT ARE PODs SHALL PURCHASE PRODUCTS UNDER THIS AGREEMENT.

The Parties, intending to be legally bound, agree as follows:

ARTICLE One
APPOINTMENT

1.1Grant. Company grants Distributor for the Term (defined below) the non-exclusive right to market, sell, distribute, and service all biologics products listed in Exhibit A ("Products") in the Territory and Field of Use specified in Exhibit B. Distributor's appointment is non-exclusive. Company may, at its sole discretion and at any time, appoint additional distributors as exclusive or non-exclusive distributors of Products in any field of use and in any geographic area, including without limitation, the Territory and the Field of Use.

1.2Limitations of Use. The Products are to be sold by Distributor directly or through other stocking distributors solely to hospitals and medical practices for use solely by licensed physicians for implantation by such physicians in their practice of medicine.

1.3Promotion. Distributor shall use its reasonable best efforts to market and sell the Products. Distributor's commitment for Products shall be limited to that which is specified on Distributor's outstanding purchase orders. During the Term, Distributor shall not directly or indirectly become an exclusive distributor of any biologics or biomaterials that compete with Company's offerings.

1.4Manufacture and Supply Commitments. During the Term, Company shall make commercially reasonable efforts to manufacture and supply to Distributor the quantities of Products that Distributor requires. Distributor will keep Company informed of Distributor's marketing plan and strategy for selling the Products in the Territory.

1.5Forecasting. Within 30 days after the Effective Date, the Parties shall negotiate in good faith to agree in writing to a commercially reasonable forecasting methodology which, given 

1Initials:  

 

EXHIBIT 10.26

reasonable efforts, assures an uninterrupted supply of Products to customers. The components of the forecasting methodology will include the following:

(a)short-term forecasts which ensure proper planning of manufacturing production to meet demand (purchase orders from Distributor to Company should be, within a mutually acceptable range, consistent with the forecast);

(b)long-term forecasts which aid Company in capacity planning and ensure optimal investments in manufacturing expansions;

(c)the forecasts shall be developed taking into account lead time requirements necessary to ramp up production as well as assuring proper supply of long lead time materials.

ARTICLE Two
PRODUCT TRANSFER PRICING AND COMPENSATION

2.1Prices, Risk of Loss, and Shipping. The Transfer Fees listed in Exhibit A are FOB shipping point, which shall be either Company's or Manufacturer's place of business, as applicable. All risk of loss or damage to the Products shall pass to Distributor at the FOB point, but Company will cooperate fully with any Distributor claims against shippers. Certain Products not manufactured by Company may be shipped directly from Company's third-party manufacturer (the "Manufacturer"). Unless otherwise agreed, Company or Manufacturer, as applicable, shall ship to Distributor's domestic facilities only. Distributor is responsible for all deliveries to Distributor's affiliates and subsidiaries, if any, and to end-users, including obtaining, at Distributor's expense, any required customs, export, and import approvals. The Transfer Prices on Exhibit A ("Transfer Prices") exclude shipping, expediting fees, and insurance, where applicable, and all state, local, and federal sales and excise taxes, all of which shall be billed separately and shall be the Distributor's sole responsibility. Prices are subject to periodic market adjustments. Company may change Transfer Prices for Products consistent with fee changes applicable to or consistent with changes applicable to Company's other customers. Company will take reasonable measures to provide advance notice of price changes.

2.2Payment Terms. Terms of payment are Net 50 days from the invoice date for Distributor's order; provided, Company may adjust such payment terms in its sole discretion based upon any factors Company deems relevant, including Distributor's payment history, frequency and volume of orders, and financial condition. Distributor guarantees payment of all receivables owed to Company resulting from its affiliates' or subsidiaries' Product purchases.

2.3Order Forms and Terms & Conditions of Sale. When placing orders for Products, Distributor shall use its purchase order form and Company's Terms of Sale in Exhibit C shall apply. Any Distributor terms that conflict with or add to the terms of this Agreement shall not apply unless the Parties mutually agree otherwise in writing. Product Returns will be governed by Exhibit D and Product Storage and Handling will be governed by Exhibit E.

2.4Rebate in Company Stock. During the Term, Distributor will earn a Rebate in shares of Company stock based on Net Transfer Volume under the formula in Exhibit A. Transfer Fees paid to Company's affiliated or subsidiary companies and invoices paid more than 50 days 

2Initials:  

 

EXHIBIT 10.26

after the invoice date will not be counted under the Rebate formula. Company shall allow a grace period which will extend until the next, immediate business day, if the last day for timely payment occurs on a weekend or holiday

2.4.1"Net Transfer Volume" means total Transfer Fees received by Company minus charges for' amounts allowed or credits for warranty claims, returns, recalls, uncollected or uncollectible accounts, services, invoices more than 50 days past due and the like. Company may offset its future stock rebate obligations for Net Transfer Volume adjustments occurring after the Rebate in Company Stock is issued, but may not claw back already issued shares.

ARTICLE Three
MATERIALS TO BE FURNISHED BY COMPANY

3.1Marketing Literature. Company will furnish Distributor technical and sales promotional material, brochures, bulletins, and specification data covering the Products. Such materials will be furnished in reasonable quantities and at no cost to Distributor, unless otherwise agreed between Company and Distributor. Except for private label literature, Distributor will not use any marketing literature or sales promotion materials in connection with the sale of the Products other than literature and materials approved in advance by Company.

3.2No Alteration. Distributor will not alter any materials supplied by Company without Company's prior written consent.

3.3Product Labeling. Company shall label and package all Products using labels and packaging as agreed between the Parties. Distributor will not alter such labeling or packaging without Company's prior written consent. Company will private label Distributor's AmBioChoice and AmBioChoice Plus human amniotic membrane allograft as reasonably agreed. Company may include advertising or other Company inserts inside packaging.

ARTICLE Four
SERVICES TO BE PROVIDED BY DISTRIBUTOR AND CUSTOMER SUPPORT

4.1Customer Support. Distributor shall support and service requirements of Product end-users and shall maintain end-user complaint files in compliance with American Association of Tissue Banks (AATB) requirements and other applicable governmental requirements. In addition, Distributor shall be responsible for Product end-user training.

4.2Customer Complaints and Recalls. Distributor shall engage in all communications with the end-users to whom Distributor sells Products. Distributor shall supply to Company within three working days of Distributor's receipt, copies of any complaints that Distributor believes are attributable to the Products. Company shall promptly notify Distributor of any suspected failures of Products, whether or not such Products have already been shipped to Distributor. If there is a problem with any Product that may affect the Product's performance, or if any governmental or regulatory authority in the Territory issues a request, directive, or order that any Product be recalled or withdrawn, or such request, directive, or order is imminent, or if a court of competent jurisdiction orders such a recall or withdrawal, Company shall determine in its sole discretion whether a product recall is necessary, and Company and Distributor shall administer any recall in accordance with applicable governmental regulations. To the extent a recall results from any cause 

3Initials:  

 

EXHIBIT 10.26

or event arising from design, manufacture, or shipment of the Products, Company (or Company's source) shall be responsible for the expense of the recall, provided Distributor shall provide Company with reasonable documentation of such expense. To the extent a recall results from any cause or event arising from Distributor's marketing, sale, promotion or distribution of, or improper storage or training with respect to the Products, Distributor shall be responsible for the expense of the recall, provided Company shall provide Distributor with reasonable documentation of such expense. In each instance, the Parties shall cooperate to efficiently administer the recall. Recall expenses shall include, without limitation, the expenses of notification, destruction, and return of the recalled or withdrawn Products and Distributor's and Company's costs for the Products recalled or withdrawn, including medical expenses.

4.3Product Sales Reports. In accordance with the applicable requirements of Medical Device Directive 93/42 EWG, ISO 13485, and AATB and "361" HCT/Ps Standards, Distributor will permanently maintain a complete record of all Products sold and installed in the Territory ("Tracking Report"). These records will list, by serial number or ID tracking number, all locations with name and address, where Products are installed. The Tracking Report shall contain sufficient information to permit complete and rapid withdrawal of a Product from the market. If a recall or the withdrawal of the Product shall occur, Distributor shall actively assist Company to ensure prompt and safe recall or withdrawal of the Product from customer and the Territory. Distributor shall retain the Tracking Report for the projected useful life of the Products sold or placed in the Territory and shall provide such Tracking Report upon request by Company. On a quarterly basis and upon termination of this Agreement, Distributor shall promptly deliver the Tracking Report to Company. Upon the delivery of the Tracking Report to Company by Distributor in the event of termination of this Agreement, Distributor will no longer be required to maintain the Tracking Report except as required by law or AATB standards.

ARTICLE Five
WARRANTY, COMPLIANCE WITH LAWS, AND INDEMNIFICATION

5.1Warranty. Company warrants that all Products will comply with legal requirements and specifications and the descriptions on its written materials provided to Distributor before or concurrently with Product shipment; provided, the Products are properly handled and stored by Distributor, and implanted by end-users, according to reasonable Company instructions. Company does not warrant or guarantee the Products against the risk of disease transmission to potential recipients. Distributor shall have no further authority to make any representations or warranties concerning the Products other than those set forth above and in medical applications in Company approved sales literature. Except as expressly provided in this Agreement, Company shall have no other responsibility or liability with respect to Products, or the use thereof, or any services supplied under this Agreement. The length of the warranty for each of the Products is 90 days after delivery to Distributor, or its end-user where the Products are shipped directly to the end-user.

5.2Company's Options in Event of Breach. In the event of a breach of any of Company's warranties, Company shall, at Company's sole option and as an exclusive remedy, promptly refund the purchase price of the defective Product or replace the Product at Company's expense, including shipping charges. If Company requests Distributor to return the defective Products, such return shall be done at Company's expense.

4Initials:  

 

EXHIBIT 10.26

5.3Use by Users. The warranty provided shall not be voided due to use of the Products by Distributor's (or its affiliates', subsidiaries' or stocking distributors') customers or end-users; provided, that Distributor and Distributor's agents, employees, and sub-distributors use and store Products in accordance with Exhibit F. Any Products constituting a biologic or synthetic substance (the "Biologics") intended to enhance cellular growth may require special handling and storage, including temperature-controlled facilities, and may require registration by Distributor within the jurisdiction of operation and sale. Distributor shall comply with all instructions for handling and storage and to obtain all necessary registrations and permits for such Biologics, and any failure to comply with the foregoing shall constitute a material breach under this Agreement and void any warranty related thereto.

5.4Disclaimer of Any Other Warranties. COMPANY MAKES NO WARRANTIES REGARDING THE PRODUCTS OTHER THAN THE EXPRESS WARRANTIES IN EXHIBIT C TO THIS AGREEMENT AND THERE SHALL BE NO IMPLIED OR STATUTORY WARRANTIES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WARRANTY AGAINST DISEASE TRANSMISSION, CONFORMITY TO MODELS OR SAMPLES OF MATERIALS OR NON-INFRINGEMENT.

5.4.1ADDITIONALLY, COMPANY MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING THE BIOLOGIC PROPERTIES OR BIOMECHANICAL PROPERTIES OF THE PRODUCTS, INCLUDING WITHOUT LIMITATION THE RISK OF DISEASE TRANSMISSION TO POTENTIAL RECIPIENTS. FOR THE PURPOSES OF THIS SECTION: (A) "BIOLOGIC PROPERTIES" MEANS THE GENETIC PROPERTIES OF A PART OR FUNCTION OF A LIVING BODY AND (B) "BIOMECHANICAL PROPERTIES" MEANS THE MECHANICAL PROPERTIES OF A PART OR FUNCTION OF A LIVING BODY, WHICH PROPERTIES DEPEND UPON THE INHERENT PROPERTIES OF THE PART OR FUNCTION'S CONSTITUENTS AND UPON HOW THE CONSTITUENTS ARE ARRANGED RELATIVE TO EACH OTHER. IN NO EVENT SHALL EITHER PARTY BE LIABLE, WHETHER AS A RESULT OF CONTRACTUAL BREACH, TORT OR OTHERWISE, TO THE OTHER PARTY FOR ANY CONSEQUENTIAL, SPECIAL, OR INCIDENTAL DAMAGES INCURRED BY SUCH OTHER PARTY, INCLUDING BUT NOT LIMITED TO INJURY TO GOODWILL, OR INDIRECT OR SPECULATIVE LOST PROFITSUNLESS SUCH LIABILITY RESULTS FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF THE OTHER PARTY. THE FOREGOING LIMITATION OF LIABILITY SHALL NOT APPLY TO THE PARTIES' RESPECTIVE CONFIDENTIALITY OBLIGATIONS HEREUNDER.

5.5Branding. Except for private labeling of Distributor's AmBioChoice and AmBioChoice Plus products, all Products shall be marketed solely under the branding and trademarks ("Trademarks") owned by Company and assigned to each of the Products. Such branding and trademarks may change from time to time at Company's sole discretion. Company grants to Distributor a limited license to the Trademarks to be used solely in the marketing of the Products during the Term of this Agreement provided that such use by Distributor is then in accordance with federal regulations concerning the marketing of medical products and any other relevant statutes and regulations. As between Company and Distributor, Company shall have the 

5Initials:  

 

EXHIBIT 10.26

exclusive right to prosecute and defend all intellectual property rights with respect to Trademarks underlying the Products.

5.6Compliance with Laws. Each Party shall comply with all applicable United States federal, state, and local laws, executive orders, rules, and regulations in connection with the performance of their respective obligations under this Agreement, including without limit: a) any requirements which may be or become applicable due to the fact that one of the equity owners of Company is a physician and surgeon whose patients may receive medical services, including implants, included among the Products, some of whom from time to time may receive financing with respect to such services under the federal Medicare or Medicaid programs; b) regulatory requirements for human cellular and tissue based products in 21 CFR Part 1271; c) standards of procedure and operation required by the American Association of Tissue Banks; and d) generally accepted industry standards related to the current good tissue practices issued by the U.S. Food and Drug Administration.

5.7Indemnification. 

(a)Definition of "Loss". A "Loss" or "Losses" shall mean any and all damages, deficiencies, claims, actions, charges, suits, proceedings, demands, assessments, judgments, orders, decrees, awards, penalties, fines, amounts paid in settlement, losses (including any diminution in value), costs, expenses, fees, obligations and liabilities (including, without limitation, costs of collection and attorneys' fees and expenses) arising from or related to any of the following:

(i)Company. In the case of Company as Indemnifying Party (as defined below), (A) any breach of or inaccuracy in any representation or warranty made by or on behalf of Company in this Agreement, (B) any breach or violation of any covenant or agreement made by or on behalf of Company in this Agreement, or (C) the failure of any Product to conform to any express warranty during the warranty period applicable thereto or, when delivered to Distributor, to conform to the specifications issued by Company, provided, however, that Company shall not indemnify Distributor to the extent that such Loss arises from the gross negligence or willful misconduct of Distributor or its customers.

(ii)Distributor.. In the case of Distributor as Indemnifying Party, (A) any breach of or inaccuracy in any representation or warranty made by or on behalf of Distributor in this Agreement, or (B) any breach or violation of any covenant or agreement made by or on behalf of Distributor in this Agreement, provided, however, that Distributor shall not indemnify Company to the extent that such Loss arises from the gross negligence or willful misconduct of Company.

(b)In General. Company shall indemnify Distributor and hold Distributor and its officers, directors, employees, agents and representatives harmless from, against, and in respect of Losses. Distributor hereby agrees to indemnify Company and hold Company and its officers, directors, employees, agents and representatives harmless from, against, and in respect of Losses.

(c)Time Limitation on Indemnification. Notwithstanding the foregoing, no claim may be made or suit instituted under this Section 5.7 unless such claim is asserted by written notice specifying to a reasonable degree the material details of the alleged breach (to the extent then 

6Initials:  

 

EXHIBIT 10.26

known) that is delivered to the other Party on or before the first anniversary of the termination or expiration of this Agreement.

(d)Third Party Claims. Promptly after the receipt by any Party entitled to indemnification under this Section 5.7 (in such capacity, an "Indemnitee") of notice of the commencement of any action against such Indemnitee by a third party (a "Third Party Claimant"), such Indemnitee shall, if a claim with respect thereto is or may be made against any party required to provide indemnification pursuant to this Section 5.7 (in such capacity, an "Indemnifying Party"), give such Indemnifying Party written notice thereof The failure to give such notice shall not relieve any Indemnifying Party from any obligation hereunder except where, and then solely to the extent that, such failure actually and materially prejudices the rights of such Indemnifying Party. Such Indemnifying Party shall have the right to defend such claim, at such Indemnifying Party's expense and with counsel of its choice reasonably satisfactory to the Indemnitee, provided that the Indemnifying Party conducts the defense of such claim actively and diligently. If the Indemnifying Party assumes the defense of such claim, the Indemnitee agrees to reasonably cooperate in such defense so long as the Indemnitee is not materially prejudiced thereby. So long as the Indemnifying Party is conducting the defense of such claim as provided in the previous sentence, the Indemnitee may retain separate co-counsel at its sole cost and expense and may participate in defense of such claim, and neither the Indemnifying Party nor the Indemnitee will consent to the entry of any judgment or enter into any settlement with respect to such claim without the prior written consent of the other, which consent will not be unreasonably withheld. If the Indemnitee reasonably determines that there may be a conflict between the positions of the Indemnifying Party and the Indemnitee in conducting the defense of any action pursuant to this Section 5.7, the counsel for the Indemnitee shall conduct the defense of such action (at the expense of the Indemnifying Party) to the extent reasonably determined by such counsel to be necessary to protect the interests of the Indemnitee and the Indemnifying Party shall employ separate counsel for its own defense. In the event the Indemnifying Party does not or ceases to conduct the defense of such claim as so provided, (x) the Indemnitee may defend against, and consent to the entry of any judgment or enter into any settlement with respect to, such claim in any manner it may reasonably deem to be appropriate, (y) the Indemnifying Party will reimburse the Indemnitee promptly and periodically for the costs of defending against such claim, including attorneys' fees and expenses, and (z) the Indemnifying Party will remain responsible for any Losses the Indemnitee may suffer as a result of such claim to the full extent provided in this Section 5.7. Each Party shall take all such actions at the expense of the other Party as may be reasonably requested by such Party in connection with such settlement or defense. If a preliminary or final judgment shall be obtained against Distributor's use of Products or any components thereof by reason of any alleged infringement, or if, in Company's opinion, a Product is likely to become subject to such a claim, Company may, at its sole option and expense:

(i)modify the Product so that the Product becomes non-infringing, but still meets the performance specifications of such Product;

(ii)procure for Distributor or its customers the right to continue to use the Product; or

(iii)substitute for the allegedly infringing Product another product meeting the performance specifications for such Product, at no additional cost to Distributor.

7Initials:  

 

EXHIBIT 10.26

(e)Additional Limits on Indemnification. Anything elsewhere in this Agreement to the contrary notwithstanding, neither Party nor any Indemnitee shall be entitled to indemnification pursuant to Section 5.7(b) of this Agreement:

(i)for any amount by which a covered Loss is increased because the Indemnitee failed to give the Indemnified Party notice thereof within a reasonable time after learning that such covered Loss exists;

(ii)for any portion of any covered Third Party Claim to the extent settled or compromised by the Indemnitee without the prior written consent of the Indemnifying Party, which consent may not be unreasonably withheld or delayed provided such settlement or compromise does not require admission of guilt and provides a complete release, while the Indemnifying Party has undertaken and continues the defense of such Third Party Claim in accordance with the terms of Section 5.7(d);

(iii)for any amount in excess of the highest bona fide offer by the Indemnifying Party to settle or compromise any covered Third Party Claim where such offer of settlement or compromise includes a complete release of, or complete covenant not to sue, the Indemnitee by the Third Party Claimant and the Third Party Claimant states in writing that such offer of settlement or compromise is unconditionally acceptable to it but the settlement or compromise is prevented from occurring by any action or any withholding of consent or approval on the part of the Indemnitee;

(iv)anything elsewhere in this Agreement to the contrary notwithstanding, it is the intention of Company and Distributor that indemnification, as provided in this Section 5.7, shall be the exclusive remedy for any and all breaches of representation, warranty, covenant, or agreement contained in this Agreement, except for specific performance of covenants specified in this Agreement, provided that the foregoing shall not limit the right of the Parties to such equitable remedies as may be available. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY AMOUNTS REPRESENTING ITS LOSS OF PROFITS, LOSS OF BUSINESS, OR INDIRECT, SPECIAL, EXEMPLARY, CONSEQUENTIAL OR PUNITIVE DAMAGES, ARISING FROM THE PERFORMANCE OR NONPERFORMANCE OF THIS AGREEMENT OR ANY ACTS OR OMISSIONS ASSOCIATED THEREWITH OR RELATED TO THE USE OF ANY ITEMS OR SERVICES FURNISHED UNDER THIS AGREEMENT, WHETHER THE BASIS OF THE LIABILITY IS BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT LIABILITY), STATUTES, OR ANY OTHER LEGAL THEORY.

ARTICLE Six
ASSIGNMENT

6.1Distributor's Rights and Obligations Nonassignable. Distributor's rights to market, promote, sell, and distribute the Products are nonassignable or otherwise transferable in whole or in part without Company's prior written consent.

6.2Assignment by Company. Company may assign this Agreement without Distributor's consent upon written notice to Distributor.

8Initials:  

 

EXHIBIT 10.26

ARTICLE Seven
TERM, MODIFICATION, AND TERMINATION

7.1Term. The initial term of this Agreement is 39 months commencing as of the Effective Date and ending December 31, 2018 (the "Initial Term"), and shall renew for successive one year periods thereafter only through advance written consent of each Party (the Initial Term together with all such renewal periods are referred to as "Term"). Any earlier modification or termination of the Term to the contrary notwithstanding, under no circumstances shall the pricing of any Products which may be sold for use in treating patients whose care is financed in whole or in part under the federal Medicare or Medicaid programs be changed outside of allowed/accepted parameters in any respect within such Term.

7.2Termination, Either Party may terminate this agreement with or without cause, upon 30 days written notice delivered to the last known address of the other Party.  Company may terminate this Agreement immediately upon the material breach of any provision hereof by Distributor.  In the event of termination or expiration of this agreement, Company shall within 90 days after such termination, have-the right to purchase from Distributor all of any inventory of Products which Distributor may have on hand that are in sellable condition and shall have purchased from Company at a price not to exceed the transfer price at which Distributor acquired  such inventory. In addition, Distributor shall to return to Company any and all property belonging to Company, including, without limitation, all sales materials, documentation, quotations, specifications, prices, confidential data, and demonstration Products, materials, and samples, and Company shall also return any like property of Distributor. No transactions voided as part of termination will be included in any Rebate calculation. Further, no Rebate will be paid for the calendar year unless Company terminates without cause.

ARTICLE Eight
ACCEPTANCE

8.1Company Acceptance. All orders placed by Distributor are subject to Company acceptance. Company may reject any order in Company's sole discretion.

ARTICLE Nine
WORK PRODUCT AND INTELLECTUAL PROPERTY

9.1Prohibition on Reverse Engineering and Ownership of Work Product. Distributor agrees not to modify, improve, reverse engineer, disassemble, analyze for reproduction, or otherwise duplicate any of the Products and further agrees not to aid any other persons or entities in doing the same. Any modifications or improvements to the Products (collectively, the "Improvements") made by Distributor shall be owned exclusively by Company, and Distributor hereby assigns, and shall ensure that its employees and officers enter into binding commitments to assign, to Company all rights, title, and interest in and to the Improvements. Company shall own all Work Product (as defined below). All Work Product shall be considered work made for hire by Distributor and owned by Company. If any of the Work Product may not, by operation of law, be considered work made for hire by Distributor for Company (or if ownership of all right, title, and interest of the intellectual property rights therein shall not otherwise vest exclusively in Company), Distributor agrees to assign, and upon creation thereof automatically assigns, without further 

9Initials:  

 

EXHIBIT 10.26

consideration, all Work Product. Company and its successors and assigns shall have the right to obtain and hold in its or their own name copyrights, registrations, patents, and any other protection available in any Work Product. "Work Product" means all intellectual property rights that relates to the business and interests of Company and that Distributor creates, invents, conceives, or develops at any time during the term of this Agreement relating to the business of Company, including all U.S. and international copyrights, patentable inventions, Trade Secrets (as defined below), discoveries, and improvements, and other intellectual property rights.

ARTICLE Ten
FORCE MAJEURE

10.1Force Majeure. Neither Party shall be held in breach of this Agreement for failure to perform any of its obligations hereunder, and the time required for performance shall be extended for a period equal to the period of such delay, provided that such delay has been caused by or is a result of any acts of God; acts of the public enemy; civil strife; wars declared or undeclared; embargoes; labor disputes, including strikes, lockouts, job actions, or boycotts; fires; explosions; floods; shortages of material or energy; events caused by reason of laws or regulations or orders by any government, governmental agency, or instrumentality, or by any other supervening unforeseeable circumstances beyond the reasonable control of the Party so affected. The Party so affected shall (a) give prompt written notice to the other Party of the nature and date of commencement of the force majeure event and its expected duration, and (b) use its reasonable best efforts to relieve the effect of such cause as rapidly as possible.

ARTICLE Eleven
INDEPENDENT CONTRACTOR AND INSURANCE

11.1Independent Contractor. Distributor is an "independent contractor," and shall use its best efforts on behalf of Company. Except as otherwise provided in this Agreement, Distributor shall not be obligated to serve Company exclusively during the Term and Company shall not be obligated to engage Distributor exclusively at any time during the Term. Distributor shall be solely responsible for all federal, state, and local taxes on Distributor's income as well as all state, local, federal sales and excise taxes, payroll unemployment and any other taxes applicable to its employees and independent contractors.

11.2Authorized Distributor. Distributor may indicate in its advertising and on its stationery that it is an authorized distributor for Company and that Products promoted by or sold by it were manufactured or distributed by Company, as the case may be. Company does not appoint Distributor as its agent, nor does Company authorize Distributor to pledge the credit of Company or to enter into any contract for Company or to bind Company in any manner.

11.3Trademarks and Trade Name. Company does not convey any property rights or interest in any trademarks, trade names or other intellectual property of Company. Distributor's use of any trademark or trade name, or other intellectual property of Company, is for the exclusive benefit of Company.

11.4Insurance. Distributor and Company shall obtain and/or maintain general liability, professional liability and product liability insurance or its equivalent amounting to at least four 

10Initials:  

 

EXHIBIT 10.26

million dollars ($4,000,000) per occurrence and four million dollars ($4,000,000) in the aggregate in view of the activities contemplated pursuant to this Agreement. Any such coverage may be satisfied under each party's own umbrella policy, if any. Each party will supply the other adequate proof of such coverage on each anniversary date of this Agreement.

ARTICLE Twelve
CONFIDENTIALITY

12.1Consequences of Entrustment with Sensitive Information. Distributor's relationship with Company requires considerable responsibility and trust. Relying on Distributor's ethical responsibility and undivided loyalty, Company agrees to and expects to entrust Distributor with highly sensitive, confidential, restricted, and proprietary information involving Trade Secrets and Confidential Information (as defined herein). Distributor should recognize that it could prove very difficult to isolate these Trade Secrets and Confidential Information from business activities that Distributor might consider pursuing after termination of Distributor's Services, and in some instances Distributor may not be able to compete with Company in certain ways because of the risk that Company's Trade Secrets and Confidential Information might be compromised. Distributor acknowledges and agrees that Distributor is legally and ethically responsible for protecting and preserving Company's proprietary rights for use only for Company's benefit, and these responsibilities may impose unavoidable limitations on Distributor's ability to pursue some kinds of business opportunities that might interest Distributor during or after Distributor's relationship with Company.

12.2Definition of "Trade Secret". A "Trade Secret" is any information, including technical or non-technical data, formulas, patterns, compilations, programs, devices, methods, techniques, drawings, processes, financial data, financial plans, product plans, or a list of actual or potential customers or suppliers which qualifies as a trade secret under applicable law. A "Trade Secret" generally (a) derives economic value, actual or potential, from not being generally known, and not being readily ascertainable by proper means, by other persons who can obtain economic value from its disclosure or use; and (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.

12.3Restrictions of Use of Disclosure of Trade Secrets. Distributor agrees not to use or disclose any Trade Secrets of Company for so long as Distributor provides the Services to Company and for so long afterwards as the pertinent item or information remains a Trade Secret, whether or not the Trade Secret is in written or tangible form, except as required to perform Distributor's Services for Company. This prohibition is in addition to any rights of Company existing under common law or applicable statutes for the protection of Trade Secrets or Confidential Information.

12.4Confidential Information. In addition, and without any intention of limiting Distributor's other obligations under this Agreement in any way, Distributor agrees, for so long as Distributor provides the Services to Company and for a period of three years following the cessation of the Services for any reason (with or without cause), not to disclose or reveal any Confidential Information concerning Company or its clients or business partners. As used herein, "Confidential Information" includes all data or information, whether or not marked "confidential" (other than Trade Secrets), that is valuable to Company (or, if owned by someone 

11Initials:  

 

EXHIBIT 10.26

else, is valuable to that third party) and not generally known to the public or to competitors in the industry, whether (a) disclosed by Company or developed by Distributor as part of Distributor's duties hereunder, or (b) disclosed to Company, or to Distributor as part of Distributor's duties hereunder, by third parties subject to obligations of confidentiality. "Confidential Information" includes Distributor's compensation from Company pursuant to this Agreement, Company's business, markets, strategic plans, or any information pertaining to the technologies and proprietary products, services, and processes of Company (particularly technology under current development or improvement), or any confidential information received from a customer or business partner of Company, unless Distributor has obtained express approval to use or disclose such information from Company in advance. Any and all material data, information, know-how, and documentation related to Company's Business, its market, its customers, its technology, its research and development, and its anticipated business which is communicated to, supplied to, or observed by Distributor that is not public information constitutes Confidential Information.

12.5Return of Materials. Upon Company's request or upon the cessation of Services, Distributor must return to Company all memoranda, notes, records, drawings, manuals, computer programs, internal or external storage devices, drives, documentation, diskettes, computer tapes, and other documents or media pertaining to the business of Company or the Services (including all copies of such materials). Distributor must also return to Company and leave at its disposal all materials involving any Trade Secrets and Confidential Information of Company. This Section 12.5 is intended to apply to all materials made or compiled by Distributor, as well as to all materials furnished to Distributor relating to the provision of the Services.

ARTICLE Thirteen
DISPUTES, GOVERNING LAW, AND VENUE

13.1Governing Law and Venue. This Agreement will be governed by and construed in accordance with the laws of the State of Georgia. Any claim arising out of or relating to this Agreement or its subject matter or any right or obligation created by this Agreement, irrespective of legal theory or claims underlying such dispute, will be brought and determined exclusively in the courts of Cobb County in the State of Georgia. Each Party irrevocably submits to the jurisdiction of courts in the State of Georgia, and agrees not to challenge jurisdiction or choice of venue for this Agreement, its subject matter, or any right, obligation, or dispute arising hereunder.

13.2Attorneys' Fees. In the event any suit or arbitration is reasonably necessary to enforce any provision of this Agreement, the non-prevailing Party shall pay the prevailing Party a reasonable sum for attorneys' fees and costs incurred by the prevailing Party. For these purposes, 'prevailing party' means the Party who is most successful in the proceedings as determined by the trial judge.

13.3Specific Performance and Consent to Injunctive Relief. Distributor agrees that Company will suffer irreparable harm if Distributor breaches any covenant in this Agreement, and that damages would be very difficult to ascertain if Distributor breached any covenant in this Agreement. The faithful observance of all covenants in this Agreement is an essential condition to Distributor's continuing relationship with Company, and Company is depending upon absolute compliance. This Agreement is intended to protect the proprietary rights of Company in many important ways. Even the threat of any misuse of the Trade Secrets or Confidential Information of 

12Initials:  

 

EXHIBIT 10.26

Company would be extremely harmful, since they are essential to the business of Company. Distributor agrees that any court or arbitrator of competent jurisdiction should immediately enjoin any breach of this Agreement upon the request of Company, and Distributor specifically releases Company from the requirement of posting any bond in connection with temporary or interlocutory injunctive relief, to the extent permitted by law.

ARTICLE Fourteen
FURTHER ASSURANCES

14.1Further Assurances. Each Party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments, and documents as the other Party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

ARTICLE Fifteen
RESTRAINT ON COMPETITION

15.1DELIBERATELY BLANK

15.2DELIBERATELY BLANK

15.3Nonsolicitation of Employees. Each Party acknowledges the substantial amount of time, money, and effort that the other Party has spent and will spend in recruitment of competent employees, and independent contractors, and agrees that it will not, during the term of this Agreement and for a period of 12 months following the termination of the Agreement for any reason (with or without Cause), solicit, or actively assist any other entity in soliciting, for employment or hire on any other basis, including as an independent contractor, any Party's employees or independent contractors. Hiring through general employment advertising is not prohibited by this clause.

15.4Nonsolicitation of Vendors or Partners. Distributor acknowledges the substantial amount of time, money, and effort that Company has spent and will spend in the development of manufacturer partnerships, and agrees that Distributor will not, during the Nonsolicitation Period, regardless of the reason of termination of this Agreement (with or without cause), (a) solicit any of Company's vendors, or manufacturing or business partners, including such entities' distributors, for business, competitive with Company's Business or otherwise, or (b) actively assist any other entity in soliciting for business any of Company's vendors or manufacturing or business partners, including such entities' distributors. This provision will not limit the scope or effectiveness of any other of Distributor's duties to Company regarding non-competition or non-solicitation, as evidenced herein or through a separate written instrument.

ARTICLE Sixteen
LIMITATION OF LIABILITY

16.1Limitation of Liability. Company will not be liable to Distributor for any indirect, incidental, delay, special, punitive, or consequential damages, including damages for lost opportunities, lost profits, loss of use, cost of capital, from this Agreement or any other transaction, 

13Initials:  

 

EXHIBIT 10.26

or lost savings, whether arising in contract, tort, or otherwise, even if such damages were foreseeable or result from a breach of this Agreement. In no event will Company's aggregate liability to Distributor exceed the amount of the fees paid by the Company to Distributor during the 12-month period immediately preceding the date the relevant claim first arose. The Parties specifically acknowledge that the pricing provisions of this Agreement reflect such allocation of risk and limitation of liabilities.

ARTICLE Seventeen
MISCELLANEOUS 

17.1Severability. If any provision of this Agreement, or the application of such provision to any person or entity or set of circumstances, is determined to be invalid, unlawful, void, or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to persons or entities or circumstances other than those as to which it is determined to be invalid, unlawful, void, or unenforceable, will not be affected and will continue to be valid and enforceable to the fullest extent permitted by law. The Parties will attempt to re-negotiate any provision deemed invalid, unlawful, void or unenforceable.

17.2Notices. All notices under this Agreement will be in writing and will be deemed to have been given and received on the earlier of the date when written notice is delivered to the address of the Party notified or three business days after the date such notice is deposited in the U.S. Mail, by registered or certified mail, postage prepaid, addressed to the address of the Party being notified. Any Party may change its address for notices by giving a written notice of address change to the other Party. Notice to the Parties will be given at the address as follows:

		
	
If to Company:
	
Vivex Biomedical, Inc.

	
:
	
1755 West Oak Parkway, Suite 200

	
 
	
Marietta, Georgia 30062

	
 
	
Attention: Ricardo Nunez, General Counsel

	
 
	
Fax: (678) 669-2006

	
 
	
 

	
If to Distributor
	
CPM Medical Consultants, LLC

	
 
	
1565 North Central Expressway, Second Floor

	
 
	
Richardson, TX 75080

	
 
	
Attention: Mark Brooks, CEO

	
 
	
Fax: (972) 354-5566

 

17.3No Waiver. Waiver by Company of any breach of this Agreement by Distributor will not be effective unless such waiver is in writing, signed by an authorized official, and references the specific breach, and no such waiver will operate or be construed as a waiver of the same or another breach on the same or any subsequent occasion.

14Initials:  

 

EXHIBIT 10.26

17.4Entire Agreement. This document is the full, complete and final agreement between the Parties as to its subject matter and supersedes any previous written or oral agreements relating to this subject which Distributor may have made with Company.

17.5Benefit. This Agreement will inure to the benefit of, and be binding upon, (i) Company, together with its successors and assigns; and (ii) Distributor, together with, as permitted, Distributor's successors, executors, administrators, personal representatives, heirs, and legatees. This Agreement is not intended to provide third-party beneficiary status to any other party, except as specificarovided herein.

17.6Section Headings. The headings contained in this Agreement are for reference purposes only and will not in any way affect the meaning or interpretation thereof.

17.7Counterparts. This Agreement may be executed in counterparts, each of which will be an original, but all of which together will constitute one instrument.

17.8Joint Language. Language in this Agreement is deemed to be the language chosen by the Parties to express their mutual intent and no rules of strict construction will be applied.

17.9Additional Representations and Warranties. Each Party represents and warrants to the other that: (a) it is not a party to or bound by any agreement or understanding, oral or written, which conflicts with or purports to prohibit it from entering into this Agreement or performing any term or provision of this Agreement; and (b) that the person whose signature appears below as signatory for it has been and is on the date hereof duly authorized by all necessary and appropriate action to execute this Agreement.

17.10Modification. This Agreement may be modified or amended from time to time only by the mutual agreement of the Parties reduced to writing and executed by them.

17.11Cumulative Remedies and Costs. Rights and remedies specified in this Agreement are in addition to all other rights and remedies a Party may have under any other agreement or applicable law, including any right to equitable relief and any right to sue for damages as a result of a breach of this Agreement (whether or not it elects to terminate this Agreement), and all such rights and remedies are cumulative.

17.12Qui Tam Waiver. If any administrative claim is made against Company, through a qui tam action under the False Claims Act or otherwise (any such claim an "Administrative Action"), to the extent permissible by law, Distributor will not be entitled to, and hereby waives and covenants not to pursue, any individual monetary relief or award or other individual remedies available to Distributor by or through such Administrative Action. The Parties agree that this Agreement does not limit either Party's right, where applicable, to file or participate in an investigative proceeding of any federal, state, or local governmental agency or authority. Distributor agrees to have all of its owners, managers, directors, officers, employees, agents, attorneys, consultants, and any other representatives individually agree to abide by the terms of this Section 17.12.

17.13Interpretation. For this Agreement, (i) the words "include," "includes" and "including" are deemed to be followed by the words "without limitation"; (ii) the word "or" is not 

15Initials:  

 

EXHIBIT 10.26

exclusive; and (iii) the words "herein," "hereof," "hereby," "hereto" and "hereunder" refer to this Agreement as a whole. Unless the context otherwise requires, references herein (x) to sections, schedules, and exhibits mean the sections of, and schedules and exhibits attached to, this Agreement; (y) to an agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted by the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation thereto and any regulations promulgated thereunder. This Agreement is to be construed without regard to any presumption or rule requiring construction or interpretation against the Party drafting an instrument or causing any instrument to be drafted. The schedules and exhibits referred to herein are to be construed with, and as an integral part of, this Agreement to the same extent as if they were set forth verbatim herein.

17.14Press Releases and Other Publicity Announcements. The timing and content of any voluntary press releases, public announcement or similar publicity regarding Product, may be issued at such time and in such manner as determined jointly by Distributor and Company. Each Party will have adequate opportunity to review and approve all such publicity, which will not be unreasonably withheld, delayed or conditioned. Communication required by law or regulation shall be preceded by reasonable notice as practical.

[Signature page follows.]

 

 

16Initials:  

 

EXHIBIT 10.26

IN WITNESS WHEREOF, the Parties have executed this Distributorship Agreement as of the Effective Date.

		
	
COMPANY
	
DISTRIBUTOR

	
Vivex Biomedical, Inc.
	
CPM Medical Consultants, LLC

	
 
	
 

	
Name: Tracy Anderson
	
Name: Mark Brooks

	
Title: CEO
	
Title: CEO

Acknowledged and Agreed:

The undersigned individual, in his capacity as a principal of Distributor, hereby agrees to comply with the terms and conditions of this Agreement, including the duties to maintain confidentiality, protect trade secrets, and refrain from reverse engineering, as described in Articles Nine and Twelve of this Agreement, and the duty to not solicit customers or employees of Company, as described in Article Fifteen of this Agreement.

	
	
 

	
Name: Mark Brooks 

	
Title: 

REMAINDER OF PAGE DELIBERATELY BLANK

 

 

17Initials:  

 

EXHIBIT 10.26

EXHIBIT A

DESCRIPTION AND TRANSFER PRICING OF PRODUCTS 

	
1.
	
Products. Distributor shall apply its best efforts in selling and marketing the following Company Products.

CPM Fee Schedule

Note: Attached are the prices as of September 17, 2015. Prices are subject to periodic market adjustments. Company may change Transfer Prices for Products consistent with fee changes applicable to or consistent with changes applicable to Company's other customers. Company will take reasonable measures to provide advance notice of price changes.

			
	
Item #
	
Item Description
	
CPM Transfer Fee Cost

	
0332
	
FF Anterior Tibialis Tendon
	
$1,500

	
0333
	
FF Posterior Tibialis Tendon
	
1,500

	
VX-2850, VX-2850r
	
Vega Cancellous Strip 50mm x 20mm x 05mm
	
700

	
VX-2857, VX-2857r
	
Vega Cancellous Strip 50mm x 20mm x 07mm
	
1,138

	
1404
	
Cancellous Crushed 15cc
	
258

	
VCA050000
	
Via Graft 5cc
	
1,500

	
VCA025000
	
Via Graft 2.5cc
	
800

	
VX-EP5
	
Vivex DBM Plus 5cc
	
529

	
VX-EP3
	
Vivex DBM Plus 3cc
	
424

	
VX-EP10
	
Vivex DBM Plus 10cc
	
929

	
ALL-0025
	
Allogen (small, 0.25m1)
	
114

	
ALL-0050
	
Allogen (medium, 0.5m1)
	
137

	
ALL-0100
	
Allogen (large, 1.0m1)
	
218

	
ALL-0200
	
Allogen (x large, 2.0m1)
	
364

	
0008
	
FF Patella Tendon w/ Bone Block Half
	
2,100

	
VX-3116, VX-3116r

TBD

1745
	
Vega Cancellous Sponges 12mm x 12mm x12mm

Vega Cancellous Sponges 10mm x 10mm x10mm

FF SemiT Tendon
	
394

394

1,138

18Initials:  

 

EXHIBIT 10.26

			
	
1746
	
FF Gracilis Tendon
	
569

	
8922
	
BTB Pre-shaped
	
TBD

	
BF2-50x10-05
	
HA/TCP Strip 50 x 10 x 5mm (tea)
	
700

	
CAS010100
	
Cygnus SoloTM Amnion Patch, 1x1cm
	
74

	
CAS020200
	
Cygnus Solon" Amnion Patch, 2x2cm
	
148

	
CAS020300
	
Cygnus SoloTM Amnion Patch, 2x3cm
	
198

	
CAS030300
	
Cygnus SoloTM Amnion Patch, 3x3cm
	
270

	
CAS040400
	
Cygnus SoloTM Amnion Patch, 4x4cm
	
442

	
CAS040600
	
Cygnus SoloTM Amnion Patch, 4x6cm
	
638

	
CAS040800
	
Cygnus SoloTM Amnion Patch, 4x8cm
	
834

	
CAS070700
	
Cygnus SoloTM Amnion Patch, 7x7cm
	
1,252

	
CAS101000
	
Cygnus SoloTM Amnion Patch, 10x10cm
	
2,502

	
CAS121200
	
Cygnus SoloTM Amnion Patch, 12x12cm
	
3,456

	
CAS021200
	
Cygnus SoloTM Amnion Patch, 2x12cm
	
638

 

	
 
	
2.
	
Rebate in Company Stock. Distributor shall earn a Rebate in Company stock, which will be transferred by April 15th of each calendar year beginning in 2016, for prior year purchases, provided Distributor meets Minimum Sales Thresholds and this Agreement has not been terminated. Distributor's 2015 calculation will include all direct purchases from Company's Marietta location beginning August 24, 2015. This includes without limit Distributor's PO # P15-0819-MARK for all items on that PO that were shipped, not returned, and paid for withindays of invoice date.

If Distributor exceeds the Minimum Sales Thresholds, the Rebate will be calculated under the following formula:

 

19Initials:  

 

EXHIBIT 10.26

 

 

20Initials:  

 

EXHIBIT 10.26

EXHIBIT B

TERRITORY

	
1.
	
Appointment of Territory. "Territory" is defined as all doctors, hospitals, clinics, or other healthcare facilities where medical treatment is administered, within and limited to the Field of Use (as defined below) AND located in the territory stipulated below:

United States of America

All Territory is assigned to Distributor on a non-exclusive basis.

	
2.
	
Field of Use. For purposes of this Agreement, the "Field of Use" includes the following fields, specialties, and indications:

	
 
	
•
	
General orthopedic, sports medicine, foot & ankle and spine use all as Company may amend from time-to-time. During the Term Company may grant exclusive distributorships for Products to other distributors.

	
3.
	
Additional Responsibilities of Distributor. Distributor shall assist in sales calls, coverage of surgeries, and any other assistance outside Distributor's Territory as may be requested by Company from time to time in order to assist in Company's overall business efforts.

 

21Initials:  

 

EXHIBIT 10.26

EXHIBIT C

TERMS OF SALE

These Terms and Conditions are incorporated into each Purchase Order in Exhibit C above as if fully written. The Purchase Order constitutes an offer by the Distributor referenced on the Purchase Order. The offer shall be deemed accepted by Company solely by Company signature of acceptance indicated on the front page of the Purchase Order.

	
1.
	
PARTIES. V ivex Biomedical, Inc., a Delaware corporation, is "Company," and the person or Company purchasing goods, as referenced on the Purchase Order, is "Distributor." All materials, goods or work described on the Purchase Order, regardless of type, are referred to as "Products."

	
2.
	
INSTALLATION AND SERVICE; PRICE ADJUSTMENTS; PAYMENT. The Product price includes all cost of future services to be rendered by Company to prepare the Products for use including, for example, the cost of an operating room representative, inventory monitoring and tray maintenance within the medical facility. These costs can be itemized upon Distributor's request. Distributor is solely responsible for any state, local, or federal sales, use, excise or other taxes and unless specifically stated, such taxes are Distributor's responsibility. Such taxes will be added to the final invoice prices in those instances in which Company is required to collect them from Distributor; provided, if Company does not collect any such taxes and is later asked by or required to pay such taxes to any taxing authority, Distributor will make such payment to Company. At Company's option, prices may be adjusted to reflect any increase in the costs of Company resulting from state, federal or local legislation or any change in the rate charge or classification of any carrier. Unless otherwise specified by Company, all prices are F.O.B. Company's plant and payment terms are net 50 days from date of invoice. Past due invoices will be subject to a service charge on the unpaid balance at an interest rate equal to the lesser of 18% per annum or the maximum allowable interest rate under applicable law. Distributor shall reimburse all expenses incurred by Company in collection, including reasonable attorneys' fees.

	
3.
	
SHIPMENT; DELIVERY; RISK OF LOSS. Title to and risk of loss of the Products shall pass to Distributor as soon as Company delivers the Products to the carrier. Each shipment date is approximate, and Company is not responsible for any damages of any kind resulting from any delay in shipment or delivery of any Products. Distributor is responsible for all shipping, delivering, handling, storage and insurance charges, such charges to be added to the final invoice or reimbursed by Distributor to Company upon Company's payment of such charges.

	
4.
	
WARRANTY. The only warranty given in respect of any Product is the express written Warranty provided by Company in Section 5 of the Distributor Agreement. COMPANY MAKES NO OTHER WARRANTY, EXPRESS OR IMPLIED, WHETHER OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OR USE OR OTHERWISE, ON THE PRODUCTS, OR ON ANY PARTS OR LABOR FURNISHED DURING THE SALE, DELIVERY, INSTALLATION, OR SERVICING OF THE PRODUCTS.

	
5.
	
CLAIMS; COMMENCEMENT OF ACTIONS; RETURNS. Distributor shall promptly inspect all Products upon delivery. No claims for shortages will be allowed unless such shortages are reported to Company within seven days after delivery. No other claims against Company relating to any Products will be allowed unless asserted in writing within 30 days after delivery of such Product. Any lawsuit or other action by Distributor based upon breach of this contract or upon any other claim arising out of this sale must be commenced within one year from the date of the tender of delivery by Company. Returns of Products by Distributor to Company must conform to the "Biologics Return Policy and Restocking Fee" at Exhibit D.

22Initials:  

 

EXHIBIT 10.26

	
6.
	
LIMITATION OF LIABILITY. IN NO EVENT SHALL COMPANY BE LIABLE TO DISTRIBUTOR FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR AS THE RESULT OF THE SALE, DELIVERY, NON-DELIVERY, INSTALLATION, SERVICING, USE OR LOSS OF USE OF THE PRODUCTS OR ANY PART THEREOF, OR FOR ANY CHARGES OR EXPENSES OF ANY NATURE INCURRED WITHOUT COMPANY'S WRITTEN CONSENT, EVEN THOUGH COMPANY HAS BEEN NEGLIGENT. IN NO EVENT SHALL COMPANY'S LIABILITY UNDER ANY CLAIM MADE BY DISTRIBUTOR EXCEED THE PURCHASE PRICE OF THE PRODUCTS IN RESPECT OF WHICH DAMAGES ARE CLAIMED.

	
7.
	
CREDIT; RIGHTS OF COMPANY. If Distributor fails to pay any indebtedness to Company promptly when due or if Distributor's performance or financial condition shall at any time seem to Company inadequate to warrant an extension of credit, Company may, if it so elects, with or without demand for any payment past due and without prejudice to any other rights or remedies available to it, take some or all of the following actions: (a) Require cash payment in advance or on delivery or on presentation of a sight draft attached to a bill of lading or such other security or proof of responsibility as is satisfactory to Company, as a condition to making further shipments of Products to Distributor or any of its customers (irrespective of whether such shipments are in fulfillment of any order already received and accepted by Company). (b) Cancel any unfilled and unshipped order or portion thereof, by Distributor for Products. (c) Apply any outstanding credits or loans due Distributor against any indebtedness owing by Distributor to Company, whether or not due or past due. If Distributor fails in any way to fulfill any of its obligations hereunder, Company may defer further shipments until such default is corrected or cancel this order and recover damages. Company shall have a security interest in, and lien upon, any property of Distributor in Company's possession as security for the payment of any amounts owing to Company by Distributor.

	
8.
	
CANCELLATIONS. After acceptance by Company, an order shall not be subject to cancellation by Distributor except with Company's advance written consent and upon terms that will indemnify Company against all direct, incidental and consequential loss or damage including, but not limited to, the losses, damages and expenses described in Section 3 above

	
9.
	
LIMITATION OF ASSIGNMENT. Neither Party may assign any of its rights or obligations hereunder without the prior written consent of the other, except that Company shall have the right to assign to any Company with which it is affiliated or to any corporation into which it shall be merged, with which it shall be consolidated, or by which it, or all or substantially all of its assets, shall be acquired or any other Company resulting from a reorganization of Company or its business segments.

	
10.
	
ENTIRE AGREEMENT. This document contains the entire agreement between Company and Distributor and constitutes the final, complete and exclusive expression of the terms of the agreement, all prior or contemporaneous written or oral communications, agreements, forms or negotiations with respect to the subject matter hereof and replaces the same in its entirety. By way of illustration and not limitation, Distributor's order shall be deemed to incorporate, without exception, all terms and conditions hereof notwithstanding any order form of Distributor containing additional or contrary terms or conditions, unless Distributor shall have expressly advised Company to the contrary in a writing apart from such order form, and no acknowledgement by Company of an order by Distributor shall be deemed to be an acceptance by Company of any such additional or contrary terms or condition. Any acknowledgement by Company of any order by Distributor is expressly conditional on Distributor assenting to, or otherwise being bound by, 

23Initials:  

 

EXHIBIT 10.26

		
any terms or conditions hereof which are in addition or contrary to the terms and conditions of Distributor's order form. No additional or contrary terms or conditions or modifications may be made to the terms and conditions contained herein except by a written instrument signed by one of Company's officers. Stenographical and clerical errors are subject to correction by Company.

	
11.
	
GOVERNING LAW. This document and the sale of all Products shall be governed by and construed in accordance with the laws of the State of Georgia. Whenever there is a conflict of laws, the substantive laws of the State of Georgia shall prevail. All disputes shall be filed solely in a court of competent jurisdiction located in Cobb County, Georgia.

	
12.
	
NO TRANSFER OF "PHI". Distributor and Company agree that Company is not a "Business Associate" as defined under HIPAA and that Distributor shall not, directly or indirectly, deliver or transfer any "Protected Health Information" (also as defined by HIPAA) to Company.

24Initials:  

 

EXHIBIT 10.26

EXHIBIT D

BIOLOGICS RETURN POLICY AND RESTOCKING FEE

All returned items require a Return Authorization number ("RA") prior to returning. To obtain an RA, contact Vivex Customer Service at customerservice@vivexbiomedical.com. Any items returned without an RA number may be considered non-returnable. All returns will be credited against the Rebate calculation.

Fresh Tissue

No return.

Freeze-Dried Tissue and Synthetic Biomaterials

May only be returned if (1) Company receives the package within ten business days from the date shipped to the designated distributor, representative, or healthcare facility, and (2) the packaging has not been opened or compromised.

There will be a 20% restocking fee applied per item.

The remaining balance will be credited upon approval and upon inspection of tissue returned.

Frozen Allograft Tissue

It is not standard practice for Company to accept frozen tissue returned from a purchaser due to strict requirements on temperature monitoring and chain of custody. Therefore, the basic considerations would be that the shipping container has not been opened or tampered with, the RA is requested within the same business day of delivery, and the total amount of time on dry ice is within 48 hours from the date shipped to the designated purchaser. Each request will be reviewed for approval on an individual basis by contacting Vivex Customer Service at the above email address.

There will be a 20% restocking fee applied per tissue item.

The remaining balance will be credited upon approval and upon inspection of tissue returned.

All frozen tissue returns, if accepted, must comply with the individual tissue bank's return policy.

Qualification

Notwithstanding the foregoing, the above return policy is subject to the terms and conditions offered by the manufacturer of the products at issue.

25Initials:  

 

EXHIBIT 10.26

EXHIBIT E

STORAGE AND HANDLING

	
 
	
1.
	
Where applicable, Distributor agrees to store and handle the Consigned Goods in accordance with:  (i) the U.S. Food and Drug Administration policy entitled Good Tissue Practice, as amended from time to time; and (ii) the manufacturer's recommended Storage Requirements and Preparation policy as set forth in the package insert that accompanies the Consigned Goods (the "Storage Requirements"). Distributor shall indemnify and hold harmless Company for any adulteration, contamination, or any other defect resulting from the failure to comply with the Storage Requirements.

	
 
	
2.
	
Distributor agrees to the following:

	
 
	
(i)
	
Distributor is prohibited from transferring any consigned allograft to another Distributor location;

	
 
	
(ii)
	
Distributor shall maintain storage conditions in compliance with The Joint Commission Regulations (TJC) Transplant Safety Standards or FDA/AATB Standards, as applicable;

	
 
	
(iii)
	
Distributor shall document receipt of each replacement graft and track the location of the graft throughout the Distributor, in compliance with TJC regulations or FDA/AATB Standards, as applicable;

	
 
	
(iv)
	
Distributor shall document each graft implantation in a clearly defined "Implant Log" that is accessible by representatives of the Product manufacturer;

	
 
	
(v)
	
Distributor shall document implant of graft on a "Tissue Utilization Record" and return to Product manufacturer; and

	
 
	
(vi)
	
Distributor shall allow representatives of the Product manufacturer to review storage, usage, purchase order, and return authorization records.

 

 

26Initials:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]